1h Free Analyst Time
The vascular endothelial growth factor (VEGF) inhibitors market is forecast to grow by USD 11.66 billion during 2023-2028, accelerating at a CAGR of 8.09% during the forecast period. The report on the vascular endothelial growth factor (VEGF) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high target affinity and specificity of VEGF inhibitors, promising pipeline and expected launches, and strategic alliances in pharmaceutical industry.
The vascular endothelial growth factor (VEGF) inhibitors market is segmented as below:
By Application
- Oncology
- Ophthalmology
By Type
- VEGF-A inhibitor
- VEGF-B inhibitor
- VEGF-C inhibitor
- VEGF-D inhibitor
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the vascular endothelial growth factor (VEGF) inhibitors market covers the following areas:
- Vascular endothelial growth factor (VEGF) inhibitors market sizing
- Vascular endothelial growth factor (VEGF) inhibitors market forecast
- Vascular endothelial growth factor (VEGF) inhibitors market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global vascular endothelial growth factor (VEGF) inhibitors market: AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer AG, Bristol Myers Squibb Co., Clovis Oncology Inc., Eisai Co. Ltd., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., LG Chem Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Viatris Inc., and Xbrane Biopharma AB.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is growing popularity of combination therapies."
According to the report, one of the major drivers for this market is the high target affinity and specificity of VEGF inhibitors.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Bayer AG
- Bristol Myers Squibb Co.
- Clovis Oncology Inc.
- Eisai Co. Ltd.
- Eli Lilly and Co.
- Exelixis Inc.
- F. Hoffmann La Roche Ltd.
- LG Chem Ltd.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
- Viatris Inc.
- Xbrane Biopharma AB
